linsitinib + pemetrexed

**OSI-906 (linsitinib) + pemetrexed** is an investigational combination therapy studied for advanced solid tumors. Linsitinib (OSI-906) is a small molecule inhibitor targeting the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR), aiming to block signaling pathways involved in tumor cell proliferation and survival. Pemetrexed is an approved antifolate antineoplastic agent that inhibits multiple enzymes involved in folate metabolism and DNA synthesis—specifically thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT)—thereby preventing cancer cell replication. Pemetrexed is primarily indicated for non-squamous non-small cell lung cancer and malignant pleural mesothelioma[1][2][3][4][5]. The combination has been evaluated in early-phase clinical trials for advanced solid tumors but has not received regulatory approval as a combination regimen[8].

Other names

OSI-906OSI906OSI 906linsitinibpemetrexed disodium